Up a level |
Freund, K Bailey; Korobelnik, Jean-François; Devenyi, Robert; Framme, Carsten; Galic, John; Herbert, Edward; Hoerauf, Hans; Lanzetta, Paolo; Michels, Stephan; Mitchell, Paul; Monés, Jordi; Regillo, Carl; Tadayoni, Ramin; Talks, James; Wolf, Sebastian (2015). TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations. Retina - the journal of retinal and vitreous diseases, 35(8), pp. 1489-1506. Lippincott, Williams & Wilkins 10.1097/IAE.0000000000000627
Schmidt-Erfurth, Ursula; Lang, Gabriele E; Holz, Frank G; Schlingemann, Reinier O; Lanzetta, Paolo; Massin, Pascale; Gerstner, Ortrud; Bouazza, Abdelkader Si; Shen, Haige; Osborne, Aaron; Mitchell, Paul (2014). Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology, 121(5), pp. 1045-1053. Elsevier 10.1016/j.ophtha.2013.11.041
Larsen, Michael; Schmidt-Erfurth, Ursula; Lanzetta, Paolo; Wolf, Sebastian; Simader, Christian; Tokaji, Erika; Pilz, Stefan; Weisberger, Annemarie; MONT BLANC Study Group, (2012). Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-related Macular Degeneration: Twelve-month MONT BLANC Study Results. Ophthalmology, 119(5), pp. 992-1000. New York, N.Y.: Elsevier 10.1016/j.ophtha.2012.02.002
Wolf, Sebastian; Holz, Frank G; Korobelnik, Jean-François; Lanzetta, Paolo; Mitchell, Paul; Prünte, Christian; Schmidt-Erfurth, Ursula; Weichselberger, Andreas; Hashad, Yehia (2011). Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR. British journal of ophthalmology, 95(12), pp. 1713-8. London: BMJ Publishing Group 10.1136/bjophthalmol-2011-300471
Holz, Frank G; Korobelnik, Jean-François; Lanzetta, Paolo; Mitchell, Paul; Schmidt-Erfurth, Ursula; Wolf, Sebastian; Markabi, Sabri; Schmidli, Heinz; Weichselberger, Andreas (2010). The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Investigative ophthalmology & visual science, 51(1), pp. 405-12. Hagerstown, Md.: Association for Research in Vision and Ophthalmology 10.1167/iovs.09-3813